Edition:
United Kingdom

Abbott Laboratories (ABT.N)

ABT.N on New York Stock Exchange

61.84USD
23 May 2018
Change (% chg)

$0.45 (+0.73%)
Prev Close
$61.39
Open
$61.26
Day's High
$61.97
Day's Low
$61.26
Volume
1,241,725
Avg. Vol
1,831,124
52-wk High
$64.60
52-wk Low
$43.40

Select another date:

Thu, May 3 2018

BRIEF-Abbott Expands Cardiac Arrhythmias Portfolio With FDA Clearance Of Advanced Mapping Catheter

* ABBOTT EXPANDS CARDIAC ARRHYTHMIAS PORTFOLIO WITH FDA CLEARANCE OF ADVANCED MAPPING CATHETER

BRIEF-Abbott's Xience Sierra Heart Stent Receives National Reimbursement In Japan

* ABBOTT'S XIENCE SIERRA™ HEART STENT RECEIVES NATIONAL REIMBURSEMENT IN JAPAN TO TREAT PEOPLE WITH CORONARY ARTERY DISEASE Source text for Eikon: Further company coverage:

BRIEF-Abbott Laboratories Says Shareholders Rejected Proposal Requesting Board Of Directors Adopt Policy That Board Chairman Be Independent Director

* ABBOTT LABORATORIES SAYS SHAREHOLDERS REJECTED PROPOSAL REQUESTING CO'S BOARD OF DIRECTORS ADOPT POLICY THAT BOARD CHAIRMAN BE INDEPENDENT DIRECTOR Source text: (https://bit.ly/2KqCwQY) Further company coverage:

BRIEF-Abbott Laboratories - Co, Sanquin Sign Multiple-Year Contract For Supply Of Primary Serological Equipment And Consumables

* ABBOTT LABORATORIES - CO, SANQUIN SIGN MULTIPLE-YEAR CONTRACT FOR SUPPLY OF PRIMARY SEROLOGICAL EQUIPMENT AND CONSUMABLES Source text for Eikon: Further company coverage: (Reuters.Briefs@thomsonreuters.com)

Abbott sticks to earlier forecasts, disappoints investors

Abbott Laboratories' just beat expectations for first quarter profits and revenue on Wednesday but stuck to a full-year profit forecast some investors had expected would be raised, sending the healthcare company's shares lower.

UPDATE 3-Abbott sticks to earlier forecasts, disappoints investors

* Analysts cite disappointment on whisper numbers among investors

BRIEF-Abbott Q1 GAAP Earnings Per Share $0.23 From Continuing Operations

* Q1 GAAP EARNINGS PER SHARE $0.23 FROM CONTINUING OPERATIONS

Abbott Labs' quarterly revenue rises 16.7 percent

April 18 Abbott Laboratories on Wednesday posted a 16.7 percent rise in quarterly revenue, helped by strong demand for its newer devices.

BRIEF-Abbott Initiates Trial To Evaluate Improved Survival And Outcomes With The Cardiomems Monitor

* ABBOTT INITIATES TRIAL TO EVALUATE IMPROVED SURVIVAL AND OUTCOMES WITH THE CARDIOMEMS MONITOR

Select another date: